Drugs / Squalamine
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02614937 | Apr 2013 → Dec 2014 | macular retinal edema, retinal vein occlusion | Ohr Pharmaceutical Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02349516 | Feb → Sep 2015 | diabetic retinopathy | Starr Muscle | Withdrawn | No outcome recorded |
| Phase 2 | NCT01769183 | Feb 2013 → Aug 2014 | retinal vascular disorder | Elman Retina Group | Completed | No outcome recorded |
| Phase 2 | NCT00244920 | Jan 2002 → Jun 2007 | prostate cancer | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT00021385 | May 2001 → ? | ovarian cancer | Jonsson Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02727881 | Apr 2016 → Dec 2017 | age-related macular degeneration | Ohr Pharmaceutical Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT00139282 | Jun 2005 → ? | wet macular degeneration | Genaera Corporation | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02511613 Comparator | Jul 2015 → Apr 2016 | age-related macular degeneration | Ohr Pharmaceutical Inc. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Squalamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01769183 ↗ |
| Known as | Squalamine lactate | “Squalamine lactate ophthalmic solution, 0.2%” NCT02727881 ↗ |
| Route | Intravenous | “squalamine lactate IV continuously” NCT00021385 ↗ |